Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study

References

• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al.. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al.. A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol. 2004;22(1):23–30.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.Br Med J. 1993;306:752–6.
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al.. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, et al.. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2011;29(33):4394–400.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Lenz H-J, et al.. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol. [Abstract (LBA385) 2012 Gastrointestinal Cancers Symposium]. 2012;30 (Supplement n°4 (February 1 supplement)).
   Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al.. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al.. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658–64.
   PubMed Web of Science ®Google Scholar
• Italiano A. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology. 2006;70:161–7.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, van Cutsem E, Siena S, Freeman DJ, et al.. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al.. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.
   PubMed Web of Science ®Google Scholar
• Au H-J, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, et al.. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol. 2009;27(11):1822–8.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al.. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(14):2311–9.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al.. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al.. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al.. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62.
   PubMed Web of Science ®Google Scholar
• Borner MM, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al.. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38(3):349–58.
   PubMed Web of Science ®Google Scholar
• Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, et al.. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 1998;4(9):2085–8.
   PubMed Web of Science ®Google Scholar
• Milano G, Ferrero JM, Francois E. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer. 2004;91(4):613–7.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, et al.. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3617–27.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al.. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3605–16.
   PubMed Web of Science ®Google Scholar
• Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, et al.. A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer. 2005;94(1):69–73.
   Web of Science ®Google Scholar
• Delord JP, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, et al.. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer. 2007;97(3):297–301.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Reitemeier RJ, Hahn RG. Mitomycin C therapy in advanced gastrointestinal cancer. J Am Med Assoc. 1968;204:1045–8.
   Web of Science ®Google Scholar
• Richards F, Case LD, White DR, Muss HB, Spurr CL, Jackson DV, et al.. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol. 1986;4(4):565–70.
   PubMed Web of Science ®Google Scholar
• Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al.. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol. 1997;8(10):995–1001.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.
   PubMed Web of Science ®Google Scholar
• Richard S. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989;10(1):1–10.
   PubMedGoogle Scholar
• Michalaki VGS, Gennatas C. Mitomycin C and UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON. 2010;15(2):270–3.
   PubMed Web of Science ®Google Scholar
• Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Föger A, Depisch D, et al.. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer — a retrospective analysis. Anticancer Drugs 2007;18:709–12.
   PubMed Web of Science ®Google Scholar
• Gundgaard M, Soerensen J, Ehrnrooth E. Third-line therapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2008;61(1):1–13.
   PubMed Web of Science ®Google Scholar
• Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, et al.. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer. 2006;95(12):1637–41.
   PubMed Web of Science ®Google Scholar
• Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res. 2003;23:2981–5.
   PubMed Web of Science ®Google Scholar
• Chong G, Dickson JLB, Cunningham D, Norman AR, Rao S, Hill ME, et al.. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93(5):510–4.
   PubMed Web of Science ®Google Scholar
• Gollasch H, Gebauer B, Sturm I, Thuss-Patience P, Pink D, Stroszczynski C, et al.. Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox. ASCO Meet Abstr. 2004;22(14_suppl):3695.
   Google Scholar
• Gyldenkerne N, Glimelius B, Frödin JE, Kjaer M, Pfeiffer P, Hansen F, et al.. A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol. 2004;43(3):276–9.
   PubMed Web of Science ®Google Scholar